»¶Ó­À´µ½ µÇ¼ δ¾­Ò×Íƹã³ÏÐÅÉóºË

±±¾©ÓÅÄ῵ÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾

²úÆ·½éÉÜ

LipoJet™ (Ver. II) DNA In Vitro Transfection Reagen

¼Û ¸ñ£º£¤2400

ÐÍ ºÅ£ºSL100468

²úÆ·ÍêÉƶȣº

Éú²úµØ£ºÆäËû·ÃÎÊÁ¿£º27´Î

·¢²¼ÈÕÆÚ£º2016/10/11 16:36:16

¸üÐÂÈÕÆÚ£º2023/10/7 10:42:17

ÏêϸÄÚÈÝ

 ÊÔ¼ÁºÐÄÚÈÝ£º

- LipoJet™ ÊÔ¼Á£¬1.0ml£¬×ã¹»ÓÃ1000´ÎDNAµÄתȾ(24¿×°åÖÐ0.5 ug DNA/¿×)×ã¹»ÓÃ1000´ÎsiRNAתȾ(24¿×°åÖÐ10 nM siRNA/¿×)¡£
- LipoJet™×ªÈ¾»º³åÒº(5X )£¬°´ÕÕ»¯µÄתȾЧÂÊÅäÖÆ£¬8.0mlŨËõÒº¾Í¿ÉÒÔÖƳÉ40mlµÄ¹¤×÷ÒºÌå¡£
²úÆ·Ìص㣺
ÊÊÓÃÓڹ㷺µÄ²¸È鶯Îïϸ°û
¼«¸ßЧÂʵØתȾDNA£¬siRNAºÍDNA/siRNA¹²×ªÈ¾
- 10 nM siRNAÄÜ´ïµ½95%µÄ³ÁĬЧӦ
ÎÞѪÇåºÍ¿¹ÉúËظÉÈÅ
¼òµ¥Ò×ÓõIJÙ×÷²½Öè
ÊÊÓÃÓÚ¸ßͨÁ¿µÄÓ¦ÓÃ
- ϸ°û¶¾ÐÔ
´¢´æÌõ¼þ £º
40C´¢´æ¡£Èô´¢²ØºÏÊÊ£¬²úÆ·µÄÎȶ¨ÐÔÄܱ£³Ö12¸öÔÂÒÔÉÏ¡£
LipoJet™ÌåÍâתȾÊÔ¼Á¾ßÓм«¹ãÆ×µÄתȾ»îÐÔ¡£

ϸ°ûÀàÐÍ

DNAתȾЧÂÊ

siRNAתȾЧÂÊ

293, 293T
3T3, NIH 3T3
3T3-L1
A549
B16-F10
BNLCL.2
C2C12
C3H/10T1/2
Caco-2
Rat primary cardiomyocytes
CHO
COS1
COS7
Human bladder carcinomal cell
mES
iMEF
HBEC
HCT116
Hela
HepG2
HT-29
HuH-7
LNCaP
MC3T3-E1
MCF10A
MCF7
MDA-MB-231
MDCK
MEF
Human primary melanocytes
Human primary melanoma
Human immortalized microglial
mIMCD-3
MRC-5
N2A
PC3
RAW 264.7
RPE
SH-SY-5Y
SK-OV-3
U-2OS
VERO

85%
-
30%
80%
75%
55%
80%
60%
20%
10%
80%
70%
75%
80%
50%
55%
45%
75%
80%
60%
45%
45%
45%
50%
40%
50%
50%
20%
50%
50%
50%
50%
50%
50%
68%
70%
45%
30%
75%
70%
80%
40%

-
90% at 20 nM
-
90% at 20 nM
-
-
90% at 40 nM
-
80 % at 30 nM
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
85% at 30 nM
85% at 30 nM
-
-
-
-
-
-
-
-
90% at 30 nM
-
-
-


ÒÔÏÂͼÀý±íÃ÷LipoJet™ÌåÍâתȾÊÔ¼ÁºÐ³öÉ«µÄDNAºÍsiRNAתȾЧÂÊ ¡£
LipoJet Transfection Reagent
A efficiency comparison of LipoJet™ reagent vs. brand name products to transfect Hela, Cos-7, NIH-3T3, CHO £ánd HEK293 (left panel) £ánd Cos-7 (right panel).  pEGFP-N3 cDNA (0.5 µg/well of 24-well plate) was transfected into different mammalian cells per the standard transfection protocols in presence of serum (10% FBS) £ánd antibiotics as recommended by manufacturers.  The transfection efficiency were analyzed via FACS 48 hours post transfection.
LipoJet_Cell_Viability
A toxicity comparison of LipoJet™ reagent vs. brand name products to transfect Hela cells.  pEGFP-N3 cDNA (1.0 µg/well of 24-well plate) was transfected to Hela cells per the standard transfection protocols in presence of serum (10% FBS) £ánd antibiotics as recommended by manufacturers.  The MTT assay (right panel) £ánd phase contrast imaging (left panel) were used to analyze the cell viability 48 hours post transfection. 
LipoJet_LIPO2000_POLYJET_Comparison_HEK293

A comparison of LipoJet™ reagent vs. Lipofectamine 2000 (L2K) £ánd PolyJet™ transfection reagent on HEK293T cell. pEGFP-N3 cDNA (0.125 µg/well, 0.25 µg/well £ánd 0.5 µg/per well of 24-well plate) was transfected into 293T cells using the standard transfection protocols in presence of serum (10% FBS) with LipoJet™ (upper panel at LipoJet™/DNA (µl/µg) ratio=2), L2K (middle panel at L2K/DNA (µl/µg) ratio=3) £ánd PolyJet™ (lower panel at at PolyJet/DNA (µl/µg) ratio=3) respectively. The cells were visualized by Nikon Eclipse Fluorescence microscope 48 hours post transfection.
LipoJet_LIPO2000_POLYJET_Comparison_HELA
A comparison of LipoJet™ reagent vs. Lipofectamine 2000 (L2K) £ánd PolyJet™ transfection reagent on Hela cell. pEGFP-N3 cDNA (0.125 µg/well, 0.25 µg/well £ánd 0.5 µg/per well of 24-well plate) was transfected into Hela cells using the standard transfection protocols in presence of serum (10% FBS) with LipoJet™ (upper panel at LipoJet™/DNA (µl/µg) ratio=2), L2K (middle panel at L2K/DNA (µl/µg) ratio=3) £ánd PolyJet™ (lower panel at at PolyJet/DNA (µl/µg) ratio=3) respectively. The cells were visualized by Nikon Eclipse Fluorescence microscope 48 hours post transfection.



LipoJet™ÊÔ¼Á½éµ¼µÄDNA/siRNA¹²×ªÈ¾±íÏÖ³öÉ«µÄ»ùÒò³ÁĬЧӦ¡£·Ö±ðÓÉLipoJet™ÊÔ¼ÁתȾGFPµÄcDNA (×óͼ, 0.25µg/¿×£¬24¿×°å)×÷Ϊ¶ÔÕպ͹²×ªÈ¾GFPµÄcDNA (0.25µg/¿×£¬24¿×°å)/GFPµÄsiRNA (ÖÕŨ¶È10 nM£¬ÓÒͼ)ÖÁHEK293ϸ°û (ÉÏͼ), Helaϸ°û(ÖÐͼ)ºÍSaoS-2ϸ°û(ÏÂͼ)¡£×ªÈ¾24Сʱºó£¬Ê¹ÓÃÄ῵EclipseÓ«¹âÏÔ΢¾µ¼ì²éGFPÓ«¹â¡£½á¹ûÏÔʾ£¬GFPµÄcDNAºÍGFPµÄsiRNA¹²×ªÈ¾µ¼ÖÂGFPµÄ±í´ï±»ÏÔÖøÒÖÖÆ¡£


LipoJet_HUVEC_mCherry-FITC-siRNA

Exceptional DNA/siRNA co-transfection efficiency on HUVEC. Co-transfection of mCherry cDNA (0.10 µg per well of 24-well plate) £ánd FITC conjugated siRNA (final 30 nM per well of 24-well plate) to HUVEC with LipoJet™ reagent gave rise to 60% mCherry+ (phase contrast overlapped with mCherry imaging, left panel) £ánd nearly 100% FITC-siRNA+ (phase contrast overlapped with FITC imaging, right panel) HUVEC 24 hours after transfection.  The pictures were given from Dr. Pan Kong of USC as courtesy.  
LipoJet_EG5_HEK293
LipoJet_EG5_HELA
Excellent silencing of endogenously expressed KIF11 (also known as EG5) in HEK293 (upper panel) £ánd Hela (lower panel) cells with LipoJet
™ reagent at 10 nM EG5 siRNA. KIF11 (also known as EG5) encodes a motor protein that belongs to the kinesin-like protein family involved in chromosome positioning £ánd bipolar spindle formation during cell mitosis. A reduction in KIF11 levels causes mitotic arrest. LipoJet™ reagent effectively delivers EG5 siRNA (final 10 nM) to HEK293 £ánd Hela cells, leading to more than 80% of "round-up" phenotype of HEK293 £ánd Hela cells 24h post transfection over negative control (final 10 nM with sham EG5 siRNA). The phenotype of "rounded-up" HEK293 £ánd Hela cells were visualized 24h post transfection with a Nikon microscope. 




Ìύѯ¼Û

¹Ø±Õ